Logo

IINNW

Inspira Technologies Oxy B.H.N. Ltd.

IINNW

Inspira Technologies Oxy B.H.N. Ltd. • NASDAQ
$0.34 ▲ 11.22% (+0.03)
Market Cap $8.19 M
52w High $0.99
52w Low $0.13
Dividend Yield 0%
P/E -0.09
Volume 19.50K
Outstanding Shares 24.08M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2023 $0 $3.152M ▲ $-3.008M ▼ 0% $-0.19 ▲ $-3.128M ▼
Q3-2023 $0 $2.642M ▼ $-2.423M ▲ 0% $-0.21 ▲ $-2.408M ▲
Q2-2023 $0 $3.048M ▼ $-2.824M ▼ 0% $-0.24 ▼ $-2.667M ▲
Q1-2023 $0 ▲ $3.287M ▲ $-2.663M ▲ 0% ▼ $-0.23 ▲ $-2.904M ▲
Q4-2022 $-4.678M $3.157M $-3.099M 66.246% $-0.28 $-3.118M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $5.779M ▲ $8.07M ▼ $3.748M ▼ $4.322M ▼
Q2-2024 $3.55M ▼ $9.422M ▲ $4.079M ▲ $5.343M ▼
Q4-2023 $7.361M ▲ $9.31M ▲ $3.572M ▲ $5.738M ▲
Q3-2023 $6.388M ▼ $8.163M ▼ $2.994M ▼ $5.169M ▼
Q2-2023 $8.967M $10.84M $3.288M $7.552M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2023 $-3.008K ▼ $0 $0 $0 $0 ▼ $0
Q3-2023 $-2.423K ▲ $0 ▼ $0 $0 $3K ▲ $0 ▼
Q2-2023 $-2.824K ▲ $1.017K ▲ $0 $0 $-3.038M ▼ $1.017K ▲
Q1-2023 $-3.031K ▲ $0 ▲ $0 ▲ $0 ▲ $-477K ▼ $0 ▲
Q4-2022 $-7.831K $-1.472M $-7.197M $-11.243M $652K $-1.644M

Five-Year Company Overview

Income Statement

Income Statement The company is still essentially pre‑revenue, with no meaningful sales showing up yet. Results are dominated by research and development and other operating costs, which lead to ongoing losses each year. Those losses appear to have narrowed recently, but that improvement comes more from cost levels and accounting effects than from any proven revenue engine. Overall, this is still very much an early‑stage income statement: expense‑heavy, revenue‑light, and dependent on future product commercialization to change the picture.

Balance Sheet

Balance Sheet The balance sheet is small and relatively simple. Assets are modest and largely made up of cash, with no reported debt, which removes interest‑payment pressure but also highlights how limited the financial cushion is. Shareholders’ equity is positive but thin, suggesting a company that has raised some capital but not yet built up a substantial asset base. This structure is typical for a young medical device developer: financially lean, with little room for prolonged setbacks unless it raises additional funds.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, reflecting ongoing spending on development, regulatory work, and overhead without incoming sales to offset it. There is essentially no outlay for heavy equipment or facilities, so the cash burn is driven mainly by people and project costs rather than big physical investments. Persistent negative free cash flow means the business relies on external financing to keep going, and that pattern likely continues until one or more products reach commercial scale.

Competitive Edge

Competitive Edge Competitively, the company is trying to carve out a new space between simple oxygen support and fully invasive mechanical ventilation. Its technology aims to treat conscious, breathing patients in a less invasive way, which, if proven in practice, would clearly differentiate it from traditional ventilators. Strong patent coverage, especially around its ART platform and blood oxygenation method, plus an OEM partnership with an established global player, help support its position. At the same time, it is tiny compared with large medical device companies, and must still prove real‑world outcomes, win clinical mindshare, and navigate competition from both existing ventilator makers and other non‑invasive respiratory devices.

Innovation and R&D

Innovation and R&D Innovation is the company’s main strength. It has a clear technology platform with several interconnected products: an initial device already cleared for surgical use, a flagship system in development for acute respiratory failure, and a non‑invasive blood sensor aimed at real‑time monitoring. The design emphasizes less invasive care, continuous data, and eventually the use of artificial intelligence for personalized treatment. A growing patent portfolio and ongoing clinical work show active R&D investment. The flip side is that much of this value is still in development and subject to regulatory review, clinical proof, and successful integration into hospital workflows.

Summary

Overall, this is a very early‑stage, pre‑revenue medical device company built around a potentially disruptive respiratory care platform. Financially, it operates with a lean balance sheet, steady cash burn, and no current sales engine, making it dependent on outside funding. Strategically, it has ambitious technology, notable patents, and a respected manufacturing partner, but faces significant execution risk in clinical trials, regulatory approvals, and market adoption against far larger incumbents. The story is driven much more by future possibilities in innovation and adoption than by current financial performance, and there is considerable uncertainty around timing and ultimate commercial scale.